Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sen Han

Showing results (161-170 of 192) with videos related to

Pageof 20
Sort By:
Annals of Palliative Medicine|August 6, 2021
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort studyXiaoling Chen, Jun Nie, Ling Dai, et al.
Cancer Immunology, Immunotherapy : CII|June 16, 2021
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLCYang Wang, Jun Nie, Ling Dai, et al.
Thoracic Cancer|January 15, 2016
Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancerJie Zhang, Shaolei Li, Xiaoling Chen, et al.
Thoracic Cancer|May 6, 2021
Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patientsXiangjuan Ma, Ziran Zhang, Xiaoling Chen, et al.
Frontiers in Oncology|May 16, 2025
Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in ChinaGuangming Tian, Jun Nie, Ling Dai, et al.
Thoracic Cancer|June 12, 2019
Salvage treatment with anlotinib for advanced non-small cell lung cancerDi Wu, Jun Nie, Ling Dai, et al.
The Science of the Total Environment|May 26, 2024
The survival, gene expression, and DNA methylation of Paralichthys olivaceus impacted by the decay of green tide and bacterial infection in both laboratory and field simulation experimentsJie Ma, Kunpeng Shi, Weijun Zhang, et al.
Journal of Thoracic Disease|July 11, 2022
The overall survival benefit in Chinese ALK<sup>+</sup> NSCLC patients received targeted therapiesGuangming Tian, Xinliang Zhao, Jun Nie, et al.
Anti-Cancer Drugs|January 19, 2024
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 studyYang Wang, Qianyun Hao, Jun Nie, et al.
Cancer Medicine|August 4, 2022
Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective studyYang Wang, Xuanye Zhang, Dan Tian, et al.
Pageof 20

Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
Annals of Palliative Medicine|August 6, 2021
Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort studyXiaoling Chen, Jun Nie, Ling Dai, et al.
Cancer Immunology, Immunotherapy : CII|June 16, 2021
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLCYang Wang, Jun Nie, Ling Dai, et al.
Thoracic Cancer|January 15, 2016
Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancerJie Zhang, Shaolei Li, Xiaoling Chen, et al.
Thoracic Cancer|May 6, 2021
Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patientsXiangjuan Ma, Ziran Zhang, Xiaoling Chen, et al.
Frontiers in Oncology|May 16, 2025
Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in ChinaGuangming Tian, Jun Nie, Ling Dai, et al.
Thoracic Cancer|June 12, 2019
Salvage treatment with anlotinib for advanced non-small cell lung cancerDi Wu, Jun Nie, Ling Dai, et al.
The Science of the Total Environment|May 26, 2024
The survival, gene expression, and DNA methylation of Paralichthys olivaceus impacted by the decay of green tide and bacterial infection in both laboratory and field simulation experimentsJie Ma, Kunpeng Shi, Weijun Zhang, et al.
Journal of Thoracic Disease|July 11, 2022
The overall survival benefit in Chinese ALK<sup>+</sup> NSCLC patients received targeted therapiesGuangming Tian, Xinliang Zhao, Jun Nie, et al.
Anti-Cancer Drugs|January 19, 2024
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 studyYang Wang, Qianyun Hao, Jun Nie, et al.
Cancer Medicine|August 4, 2022
Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective studyYang Wang, Xuanye Zhang, Dan Tian, et al.
Pageof 20